hydroxychloroquine has been researched along with Birth Weight in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate pregnancy safety of hydroxychloroquine (HCQ) for rheumatologic diseases." | 7.79 | Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. ( Blyakhman, S; Diav-Citrin, O; Ornoy, A; Shechtman, S, 2013) |
| "The use of hydroxychloroquine (HCQ) in pregnancy remains controversial." | 5.10 | Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. ( Amoura, Z; Costedoat-Chalumeau, N; Denjoy, I; Duhaut, P; Huong, DL; Lupoglazoff, JM; Piette, JC; Sebbough, D; Vauthier, D; Wechsler, B, 2003) |
| "To evaluate pregnancy safety of hydroxychloroquine (HCQ) for rheumatologic diseases." | 3.79 | Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. ( Blyakhman, S; Diav-Citrin, O; Ornoy, A; Shechtman, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diav-Citrin, O | 1 |
| Blyakhman, S | 1 |
| Shechtman, S | 1 |
| Ornoy, A | 1 |
| Costedoat-Chalumeau, N | 1 |
| Amoura, Z | 1 |
| Duhaut, P | 1 |
| Huong, DL | 1 |
| Sebbough, D | 1 |
| Wechsler, B | 1 |
| Vauthier, D | 1 |
| Denjoy, I | 1 |
| Lupoglazoff, JM | 1 |
| Piette, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441] | Phase 2 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to Not started) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydroxychloroquine and Birth Weight
| Article | Year |
|---|---|
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group.
Topics: Antirheumatic Agents; Birth Weight; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hydr | 2003 |
1 other study available for hydroxychloroquine and Birth Weight
| Article | Year |
|---|---|
Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Birth Weight; Crohn | 2013 |